Nektar Therapeutics (NKTR) Non-Current Debt (2012 - 2020)

Nektar Therapeutics' Non-Current Debt history runs 9 years deep, the most recent figure standing at $254.8 million for Q1 2020.

• In Q1 2020, Non-Current Debt rose 3.0% year-over-year to $254.8 million; the TTM figure through Mar 2020 stood at $254.8 million (up 3.0% YoY), while the FY2018 annual figure was $247.0 million, up 0.71% from the prior year.
• Non-Current Debt was $254.8 million for Q1 2020 at Nektar Therapeutics, up from $248.3 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $254.8 million in Q1 2020 to a low of $242.1 million in Q1 2016.
• Historically, Non-Current Debt has averaged $245.8 million across 5 years, with a median of $245.4 million in 2017.
• The sharpest annual moves came in 2016 and 2019: Non-Current Debt surged 94.05% in 2016, then gained 0.71% in 2019.
• A 5-year view of Non-Current Debt shows it stood at $243.5 million in 2016, then grew by 0.72% to $245.2 million in 2017, then grew by 0.71% to $247.0 million in 2018, then gained by 0.53% to $248.3 million in 2019, then rose by 2.64% to $254.8 million in 2020.
• The last three Non-Current Debt figures came in at $254.8 million (Q1 2020), $248.3 million (Q3 2019), and $247.8 million (Q2 2019), per Business Quant data.